Review Article

Neuroprotective Mechanisms of PPARδ: Modulation of Oxidative Stress and Inflammatory Processes

Caroline I. Schnegg1,2 and Mike E. Robbins1,2,3

1 Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
2 Brain Tumor Center of Excellence, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
3 Department of Radiation Oncology, Comprehensive Cancer Center, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA

Correspondence should be addressed to Mike E. Robbins, mrobbins@wfubmc.edu

Received 28 July 2011; Accepted 25 August 2011

Academic Editor: Paul Drew

Copyright © 2011 C. I. Schnegg and M. E. Robbins. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peroxisome proliferator-activated receptors (PPARα, δ, and γ) are ligand-activated transcription factors that regulate a wide range of cellular processes, including inflammation, proliferation, differentiation, metabolism, and energy homeostasis. All three PPAR subtypes have been identified in the central nervous system (CNS) of rodents. While PPARα and PPARγ are expressed in more restricted areas of the CNS, PPARδ is ubiquitously expressed and is the predominant subtype. Although data regarding PPARδ are limited, studies have demonstrated that administration of PPARδ agonists confers neuroprotection following various acute and chronic injuries to the CNS, such as stroke, multiple sclerosis, and Alzheimer’s disease. The antioxidant and anti-inflammatory properties of PPARδ agonists are thought to underly their neuroprotective efficacy. This review will focus on the putative neuroprotective benefits of therapeutically targeting PPARδ in the CNS, and specifically, highlight the antioxidant and anti-inflammatory functions of PPARδ agonists.

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. Three closely related subtypes have been identified—PPARα (NR1C1), PPARδ (NR1C2, PPARβ), and PPARγ (NR1C3) [1]. They are ligand-activated transcription factors that heterodimerize with the retinoid X receptor to regulate transcription [2, 3]. Each PPAR subtype is encoded by a different gene and has a unique tissue distribution. PPARs possess a high degree of structural homology and share the same DNA response element, termed the PPAR response element (PPRE). PPREs consist of an AGGTCA hexameric direct repeat separated by one or two nucleotides [4]. Despite sharing PPREs, the three subtypes have both similar and different functions. The specificity of their functions appears to depend on their differential (i) tissue expression, (ii) ligand specificity, (iii) A/B-domain, (iv) posttranslational modifications, (v) affinity for cofactors, (vi) affinity for individual PPREs, and (vii) nongenomic actions [5].

A common function of the PPAR subtypes is suppressing oxidative stress and inflammatory processes [6]. Although the CNS was once thought to be immune privileged due to the protection of the BBB, numerous studies have demonstrated that inflammation does occur in the brain and spinal cord and is associated with many neurodegenerative disorders [7]. These findings provided the original rationale for assessing the neuroprotective efficacy of PPAR agonists in a variety of CNS disorders. The neuroprotective efficacy of PPARα and PPARγ agonists has been reviewed previously [8–10].

Despite being the predominant subtype in the CNS [11], data regarding the neuroprotective efficacy of PPARδ agonists are limited compared to PPARα or PPARγ agonists. This likely reflects the fact that PPARδ-specific agonists and antagonists have only recently become available. Several studies have used the synthetic PPARδ-specific agonists L-165041, L-160,043, GW0742, or GW501516 to explore the functional activities of the receptor [12–15]. Recent studies assessing...
the neuroprotective efficacy of synthetic PPARδ agonists indicate that they may ameliorate clinical symptoms and reduce the severity of a variety of acute and chronic CNS pathologies, in large part, by modulation of oxidative stress and inflammatory responses associated with the diseases. Recent reports suggest that PPARδ may have additional protective effects against the progression of CNS disorders, such as promoting cell survival [12, 13, 16]. To date, the neuroprotective benefits of PPARδ agonists have been observed in models of stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, radiation-induced brain injury, and spinal cord injury [12, 17–23].

2. PPARδ Expression in the CNS

The expression of PPARδ has been examined in many rodent tissues, including the CNS. The receptor is thought to be ubiquitously expressed in the adult rodent brain and spinal cord [11, 24–26]. In rats, PPARδ begins to be expressed at midgestation, reaching peak expression in all neural tissues in the late stage embryonic brain, suggesting that it may play a role in cell differentiation in the CNS [27]. In situ hybridization and immunolocalization studies have demonstrated that high levels of PPARδ are found in the hippocampus, telencephalic cortex, and the cerebellar cortex of rats [11, 27, 28]. Other studies in the rat brain indicate that PPARδ mRNA is highly expressed in the thalamic nuclei [25]. In the rat spinal cord, PPARδ is the most abundant PPAR subtype; it is expressed in every cell layer and highly expressed in the lamina II and lamina IX layers [11]. Rat brain endothelial cells also express PPARδ mRNA, suggesting a possible role in blood-brain barrier (BBB) maintenance [29]. PPARδ is also widely expressed in the mouse brain, with high levels in the entorhinal cortex, hypothalamus, hippocampus, and corpus callosum. Localization studies identified PPARδ mRNA and protein in mouse neurons and oligodendrocytes, but not in astrocytes [26]. However, in cell culture, PPARδ expression has been documented in mouse and rat cortical astrocytes as well as in rat cerebral astrocytes [30, 31]. Results from our own laboratory demonstrate that the receptor is also expressed in microglia. Taken together, PPARδ expression has been observed in all the major cell types within the CNS, including astrocytes, endothelial cells, microglia, neurons, and oligodendrocytes.

3. Stroke-Induced Brain Injury

Strokes are often caused by a blockage of blood flow in the brain, referred to as ischemia, which results in a shortage of oxygen to the brain. Vascular degradation after cerebral ischemia leads to BBB disruption and neuronal loss. Of the three PPAR isotypes, PPARδ is the highest expressed in the brain’s parenchyma and cerebral vasculature, and increasing evidence suggests that PPARδ may protect against ischemic insults [13]. This was first highlighted in PPARδ-null mice, which compared to WT mice, had a significant increase in infarct size after focal cerebral ischemia [17, 18]. The difference in infarct size was detected as early as 30 min after induction of ischemia, suggesting that PPARδ plays an early role in protection [17]. Following middle cerebral artery occlusion (MCAO), increased cerebrovascular permeability and infarct size were detected in mice with specific deletion of PPARδ in vascular smooth muscle cells (VSMCs) [13]. Additionally, PPARδ agonists appear to be protective after cerebral ischemia; rats given infusions of L-165041 or GW501516 had significantly attenuated ischemic damage 24 h after MCAO [12]. The mechanisms underlying the protective effect of PPARδ, however, are unclear. Potential protective effects include (i) modulating oxidative stress and proinflammatory responses, (ii) maintaining matrix-cell adhesions, and (iii) promoting cell survival.

The enhanced oxidative stress and inflammatory responses in an ischemic brain are thought to contribute to neuronal death. The antioxidant and anti-inflammatory actions of PPARδ agonists have been observed in a variety of cell types, including astrocytes and microglia [32–35]. In particular, PPARδ can activate transcription of antioxidant genes, including catalase and superoxide dismutase (SOD) [36–38]. PPARδ can also control gene transcription independent of binding to PPREs. Transrepression is thought to underlie many of the anti-inflammatory effects of PPARδ. PPARδ can exert transrepression by directly interacting with nuclear factor-κB (NF-κB), thereby inhibiting activation of the proinflammatory transcription factor [38]. In addition, PPARδ exerts transrepression in macrophages by relocating the transcriptional repressor B-cell lymphoma protein 6 (Bcl-6) from PPARδ to the promoter regions of proinflammatory genes, including the vascular cell adhesion molecule-1 (VCAM-1) and the monocyte chemoattractant protein-1 (MCP-1) [39–41].

It is possible that modulation of these processes contributes to the protective effect of PPARδ after cerebral ischemia. In an in vivo model of MCAO, for example, there was an increase in the lipid peroxidation marker, malondialdehyde, and a decrease in the levels of the antioxidant, glutathione, and the antioxidant enzyme, manganese (Mn)SOD, in PPARδ-null mice compared to WT mice. This suggests that there is increased oxidative stress in PPARδ-null mice following cerebral ischemia [18]. Additionally, mice with PPARδ specifically deleted in their VSMCs had a significant increase in proinflammatory mediators in their brain 24 h after MCAO. This included an increase in the mRNA levels of interleukin-1 beta (IL-1β), IL-6, intercellular adhesion molecule-1 (ICAM-1), and MCP-1 [13]. Pioglitazone, a PPARγ agonist, has been shown to confer neuroprotection following MCAO. This is thought to occur, in part, by activation of PPARδ, which enhances production of the IL-1 receptor antagonist (IL-1Ra). IL-1Ra promotes neuroprotection by competing with binding of IL-1β to IL-1R1; consequently, this represses receptor signaling and reduces inflammatory responses following ischemia [42].

The pathogenesis of cerebral ischemia also involves the breakdown of matrix-cell adhesions, which results in the disruption of the BBB and ultimately neuronal death and brain damage. PPARδ may regulate these responses by decreasing activity of matrix metalloproteinases (MMPs),
enzymes that degrade structural proteins in the extracellular matrix and that have been implicated in ischemia-induced parenchymal and vascular damage. In particular, treatment of VSMCs with the PPARδ agonist, GW501516, reduced MMP-9 enzymatic activity 24 h after oxygen-glucose deprivation (OGD). Furthermore, VSMC-selective PPARδ knockout mice exhibited increased MMP-9 expression following MCAO, and inhibition of MMP-9 using shRNA reduced infarct size and vascular permeability in these mice [13]. More studies, however, are needed to understand the mechanism by which PPARδ regulates MMP-9 expression.

PPARδ may also promote cell survival after ischemic insults. In particular, GW501516 significantly reduced cerebral vascular endothelial cell degeneration in an OGD mouse model. GW501516 protected against vascular cell death by inhibiting expression of miR-15a, which directly regulates the antiapoptotic protein Bcl-2. This resulted in increased Bcl-2 protein expression, reduced Golgi fragmentation, and decreased caspase-3 activity, which in turn reduced cerebrovascular permeability and infarct volume in vivo [43]. Although not tested with respect to protection against stroke-induced injury, PPARδ has been shown to promote survival of neurons under stress conditions. Specifically, L-165041 or GW501516 significantly reduced SH-SY5Y cell death after exposure to (i) thapsigargin, an endoplasmic reticulum Ca2+-ATPase inhibitor; (ii) 1-methyl-4-pheylpyridinium (MPP+), a dopaminergic neurotoxin; or (iii) staurosporine, a protein kinase inhibitor. The effect on viability may be due to inhibition of apoptosis, as both agonists could significantly attenuate caspase-3 and caspase-7 activity in cells treated with one of the three cytotoxins [12]. GW0742 has also been shown to be neuroprotective in primary cultures of rat cerebral granule neurons exposed to low-KCl media. Prolonged exposure of primary cultures to GW0742, however, induced apoptotic cell death [44]. Future studies should examine if, similar to vascular endothelial cells, PPARδ agonists can also promote neuronal survival after ischemic insults.

4. Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease that results in the expansion of pathogenic T cells specific for myelin autoantigens [45]. The disease manifests in the destruction of myelin sheaths and the inflammatory activation of glial cells [46]. Experimental autoimmune encephalomyelitis (EAE), in which mice are immunized with the encephalitogenic myelin oligodendrocyte glycoprotein (MOG) peptide, is used as a model of MS [47, 48]. The potential role of PPARδ in demyelinating diseases was first proposed in a model that attempted to explain the detrimental effects of inflammatory mediators on myelin synthesis. Specifically, tumor necrosis factor alpha (TNF-α), a cytokine implicated in demyelinating pathologies, was demonstrated to attenuate PPARδ expression in OPCs and, concurrently, decrease very long-chain fatty acid (VLCFA) β-oxidation. The hypothetical model proposed that decreased PPARδ expression would lead to VLCFA accumulation, which would induce cytotoxic effects and demyelination. PPARδ agonists, therefore, were postulated to be beneficial for MS-affected individuals [49].

GW0742 was the first PPARδ agonist to show beneficial effects in a mouse model of EAE [14, 20]. The effects of GW0742 were greater when administered to mice during disease progression, rather than when given at the time of MOG administration. Specifically, GW0742 reduced the emergence of new cortical lesions, increased proteolipid protein (PLP) mRNA levels, and reduced IL-1β levels [14]. The levels of interferon-gamma (IFNγ) were not altered by GW0742, which is in contrast to observations in mouse and human immune cells that demonstrate GW0742 can inhibit production of IFN-γ [14, 20]. The protective effects of GW0742 are likely mediated by reducing inflammatory cell activation [14].

Research indicates that GW501516 and L-165041 are also effective at ameliorating EAE. In mice, the attenuation of EAE by GW501516 or L-165041 was associated with decreased expression of the proinflammatory cytokines, IL-2 and IL-23, and increased expression of the anti-inflammatory cytokines, IL-4 and IL-10. Reduced production of IFNγ and IL-17 by T helper type 1 (Th1) and Th17 cells was also observed in EAE mice treated with GW501516 or L-165041 [50]. In accord with these findings, PPARδ-null mice with EAE had impaired Th1/Th17 and Th2/Treg responses, which may contribute to the extended recovery time in PPARδ-null mice compared to WT mice. The prolonged EAE in PPARδ-null mice was associated with sustained levels of IFNγ, IL-17, IL-12p35, and IL-12p40, consistent with the hypothesis that PPARδ regulates inflammatory responses associated with EAE [19].

PPARδ-null mice with EAE also exhibited a severe inflammatory response in their spinal cord—they had a higher frequency of CD4+ cells that had an accumulation of IFN-γ or IL-17A compared to WT mice [20]. Intriguingly, PPARδ also appears to play a protective role in the spinal cords of steroid-receptor-coactivator-3-(SRC-3-) null mice with EAE. SRC-3-null mice had a significantly reduced severity of EAE that was associated with diminished inflammatory responses and decreased demyelination. The attenuated EAE symptoms in SRC-3-null mice are thought to occur via upregulation of PPARδ. SRC-3-null mice displayed decreased expression of the proinflammatory markers, TNF-α, IFN-γ, CCL2, CCL3, CCL5, and CXCL10, and increased expression of the anti-inflammatory markers, IL-10 and opsonins. Myelin genes—myelin basic protein (MBP) and PLP—were also significantly higher in SRC-3-null mice, which may be a result of increased PPARδ expression [51].

In SRC-3 mice, PPARδ expression is thought to alternatively activate microglia from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In particular, there was a correlation between PPARδ expression in SRC-3-null mice and ramified microglia that expressed Ym1/2 and Mrcl, phenotypic markers for alternative activation. Interestingly, PPARδ activation has been shown to control the alternative activation of adipose tissue macrophages (ATMs) and Kupffer cells, hepatic macrophages [52, 53]. In the white adipose tissue of PPARδ-null mice, genes of alternatively activated macrophages, Clec7a, Retnla, Tgfb1,
Jag1, and Mrcl, were reduced. The alternative activation of Kupffer cells was also decreased in PPARδ-null mice, as assessed by reduced expression of Arg1, Clec7a, Jag1, Pdcd11g2, and Chia [53]. Reduced alternative activation of ATMs and Kupffer cells in PPARδ-null mice led to impaired glucose tolerance and insulin resistance [52, 53]. Whether PPARδ agonists can alternatively activate microglia remains to be determined.

To further examine the mechanisms by which PPARδ is protective in models of EAE, studies have used in vitro models of aggregating brain cells. GW501516 was effective at reducing IFN-γ- or lipopolysaccharide-(LPS-) induced TNF-α or inducible nitric oxide synthase (iNOS) mRNA levels; however, it increased IL-6 mRNA expression. In the presence of anti-MOG, a demyelinating antibody, GW501516 was unable to prevent decreases in MBP [54]. These results further suggest that in models of EAE, the protective effects of PPARδ agonists may be due to their anti-inflammatory properties rather than their effects on myelin genes or oligodendrocytes. Collectively, the findings above indicate that PPARδ agonists ameliorate the inflammatory responses in EAE and may represent therapeutic avenues to ameliorate MS progression.

5. Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by neuronal degeneration and progressive cognitive impairment [55]. While the pathogenesis of AD is not fully understood, AD patients exhibit an accumulation of amyloid plaques formed by oligomerization of the amyloidogenic peptides, Aβ 1–42 and Aβ 1–40, and neurofibrillary tangles formed by tau protein. These plaques and tangles are thought to contribute to neurodegeneration [56]. Inflammatory cytokines may lead to an increase in Aβ peptides, thereby contributing to the progression of AD. The neurotransmitter noradrenaline (NA) can protect neurons from various inflammatory stimuli, including exposure to Aβ peptides. This is thought to occur, in part, by activation of PPARδ. In particular, in primary cultures of rat cortical neurons, Aβ peptides induced cell death as measured by LDH release. The ability of NA to prevent Aβ peptide-induced cell death was decreased in the presence of GW9662, a PPAR antagonist. Moreover, GW0742 blocked cell death at the same degree as NA, as measured by LDH release and FluoroJade B staining [21].

Further supporting the possible benefits of targeting PPARδ in the treatment of AD, administration of GW0742 significantly reduced amyloid plaque burden in the subiculum of 5xFAD mice. These mice overexpress the amyloid precursor protein and presenilin 1, display plaques and inflammation, and develop neuronal damage and cognitive impairment. Interestingly, the decrease in amyloid burden in GW0742 treated 5xFAD mice was associated with increased expression of neprilysin, an amyloid-degrading enzyme. Furthermore, GW0742 could activate a neprilysin promoter driving luciferase expression in vitro. GW0742 also led to a decrease in astrocyte activation in the 5xFAD mice, as assessed by GFAP staining [22].

Streptozotocin (STZ) administered to mice intracerebrally depletes brain insulin levels and induces progressive neurodegeneration that corresponds to the clinical symptoms of AD. Impairments in insulin and insulin-like growth factor signaling are observed in AD brains and these abnormalities increase concomitantly with dementia [57, 58]. Treatment with the PPARδ agonist, L-160,043, prevented STZ-induced neurodegeneration and ameliorated cognitive impairment as evaluated by the Morris Water Maze task. These effects of L-160,043 were attributed to (i) increased insulin receptor signaling, (ii) reduced tau phosphorylation, (iii) increased choline acetyltransferase, and (iv) attenuated inflammation and oxidative stress. Consistent with the effects of GW0742 described above, L-160,043 reduced levels of GFAP. Furthermore, L-160,043 reduced immunoreactivity of the oxidative stress markers, 8-hydroxyguanosine (8-OHdG) and 4-hydroxynonenal (HNE), relative to STZ-treated animals [15]. Elevated levels of 8-OHdG and HNE have been detected in AD brains [59, 60]. This suggests that PPARδ agonists may be efficacious antioxidant agents to ameliorate oxidative stress associated with AD. Interestingly, the actions of L-160,043 were more pronounced than the PPARα agonist, GW7647, or partial PPARγ agonist, F-L-Leu [15]. It is important to note that the PPARδ agonist was administered the same day as STZ. Future studies should assess whether PPARδ activation at later stages of AD progression can also halt AD development.

6. Parkinson’s Disease
PPARδ agonists may exert therapeutic benefits in patients with Parkinson’s disease (PD), a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra. Progression of PD has been attributed to reactive oxygen species (ROS) and oxidized dopamine, which are toxic to dopaminergic neurons [61]. This disease manifests itself in motor dysfunctions and tremors. The synthetic opiate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces PD in drug-addicted individuals. In mice, administration of GW501516 or L-165041 48 h before the first injection of MPTP significantly ameliorated depletion of striatal dopamine and its metabolites. As mentioned above, these PPARδ agonists also protected human neuroblastoma cells, SH-SY5Y, from cell death induced by the dopaminergic neurotoxin MPP+. This protection was associated with a significant reduction of caspase-3 and may contribute to the neuroprotective efficacy of GW501516 and L-165041 in experimental models of PD [12]. The protective role of PPARδ in PD has not been adequately explored, and it is unclear if, similar to the PPARγ agonist pioglitazone, PPARδ agonists can modulate oxidative stress and inflammatory processes associated with PD. In particular, in a mouse model of PD, pioglitazone prevented MPTP-induced glial cell activation and loss of dopaminergic neurons. Mechanistically, neuronal death was prevented by inhibiting activation of the proinflammatory transcription
factor NF-κB by (i) increasing Iκ-Bα expression and (ii) inhibiting nuclear translocation of p65. Pioglitazone also decreased the number of GFAP and iNOS positive cells in both the striatum and substantia nigra pars compacta [62].

7. Astrogliosis

Many CNS disorders are associated with astrogliosis. During astrogliosis, astrocytes are thought to increase production of proinflammatory mediators, such as arachidonic acid [63, 64]. Arachidonic acid, which is a substrate for cyclooxygenase-1 (Cox-1) and Cox-2, is released by phospholipase A2 (PLA2). PLA2 and Cox-2 have been associated with neurodegenerative diseases [65, 66]. Interestingly, both secretory PLA2 (sPLA2) and cytosolic PLA2 (cPLA2) contain a PPRE in their promoters. PPARδ expression appears to be abundant in immature cultures of primary rodent astrocytes [30]. In primary rat brain astrocytes, pretreatment of astrocytes with L-165041 attenuated LPS-induced sPLA2 expression, while astrocytes treated simultaneously with L-165041 and LPS displayed increased cPLA2 expression and had no change in sPLA2 expression. As the authors noted, LPS stimulates NF-κB and activator protein-1 (AP-1), which PPARs have been shown to transrepress. It is possible that in this model LPS-induced activation of NF-κB and AP-1 is acting to transrepress PPARδ [35]. Furthermore, LPS-induced Cox-2 expression in rat primary astrocytes may be modulated, in part, by PPARδ. In particular, rosiglitazone, a PPARγ agonist, increased PPARδ expression in cortical astrocytes and led to increased Cox-2 expression. On the other hand, GW7647, a PPARα agonist, reduced PPARδ levels and decreased LPS-induced Cox-2 expression [67]. These results are surprising given that studies largely focus on the antioxidant and anti-inflammatory properties of PPARs.

8. Radiation-Induced Brain Injury

Fractionated partial or whole-brain irradiation (fWBI) is often required to treat both primary and metastatic brain cancer. Radiation-induced brain injury, including progressive cognitive impairment, however, can significantly affect the well-being of the approximately 200,000 patients who receive these treatments each year [68, 69]. Recent reports indicate that the pathogenesis of radiation-induced brain injury may be caused, in part, by chronic oxidative stress and inflammatory responses, as well as increased microglial activation in the brain [70–72]. Microglia, which are termed the macrophages of the brain, are considered to be one of the key mediators of neuroinflammation [73–75]. Data suggest that irradiating microglial cells in vitro leads to an increase in a variety of proinflammatory mediators, including the cytokines, TNF-α and IL-1β, and the chemokines, MCP-1 and ICAM-1 [76–78]. Studies performed in vivo indicate that there is an increase in proinflammatory mediators within hours of irradiating the rodent brain [76, 79]. To date, studies in rodents have demonstrated that administration of anti-inflammatory drugs can decrease radiation-induced microglial activation [80, 81]. These findings provide a strong rationale for investigating whether administration of PPARδ agonists can confer neuroprotection following irradiation.

Ongoing studies in our laboratory are investigating the ability of PPARδ to modulate radiation-induced brain injury. Incubating BV-2 murine microglial cells with the PPARδ agonist, L-165041, is effective at modulating radiation-induced injury, including inhibiting the radiation-induced increase in (i) intracellular ROS generation, (ii) Cox-2, iNOS and MCP-1 expression, (iii) IL-1β and TNF-α message levels, and (iv) NF-κB and AP-1 activation (unpublished results). These observations demonstrate the important antioxidant and anti-inflammatory actions of PPARδ agonists in microglial cells following irradiation and are similar to previous findings indicating that the PPARα agonists, GW7647 and fenofibrate, can inhibit radiation-induced inflammatory markers in BV-2 cells [82].

Our laboratory has also assessed the anti-inflammatory actions of PPARδ following irradiation in vivo. One week following a single dose of 10 Gy 137Cs y WBI, young adult male C57Bl/6 mice exhibited a significant increase in the number of activated microglia (CD68+ cells) in the dentate gyrus (DG). GW0742 administered prior to, during, and after WBI prevented this radiation-induced increase in activated microglia. Interestingly, radiation did not induce an increase in activated microglia in the DG of PPARδ-null mice at one week or two months after WBI. These results suggest that PPARδ deficiency leads to an inhibition of microglial activation (unpublished results). These findings are surprising and quite different from those observed in PPARα-null mice, where PPARα deficiency resulted in a sustained increase in activated microglia seen at one week and two months after WBI [81]. This indicates that the effect of PPAR deficiency is subtype-dependent.

Although PPARδ-null mice do not show a radiation-induced microglial response, they may display an astrocitic response. Of note, PPARδ-null mice express increased mRNA levels of GFAP, a marker of astrocytes, compared to WT mice. Additionally, while WBI reduced the number of astrocytes, GFAP+ cells, two months after irradiation in WT mice, there was no apparent decrease in the number of astrocytes in the irradiated PPARδ-null mice. While these findings are preliminary, they do suggest that PPARδ may modulate the radiation response of the astrocyte (unpublished results).

Although studies have not examined if PPARδ agonists can modulate radiation-induced cognitive impairment, data demonstrate that PPARγ can ameliorate or prevent radiation-induced cognitive decline. In particular, pioglitazone ameliorated radiation-induced cognitive impairment when administered prior to, during, and for 4 or 54 weeks after fWBI of young adult male rats [83]. While these results are promising, there are concerns with using pioglitazone in the clinic, including an increased risk of (i) weight gain and (ii) myocardial infarctions [84]. It is important to investigate if, similar to PPARγ, PPARδ can modulate radiation-induced cognitive impairment. Since PPARδ is the primary subtype in the CNS, it is possible that PPARδ agonists can mediate a more pronounced antioxidant and anti-inflammatory response in the brain.
Table 1: The neuroprotective benefits of PPARδ agonists.

| CNS disorder          | PPARδ agonist | Neuroprotective benefits                                                                                                                                                                                                 |
|-----------------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Stroke                | GW501516      | Significantly attenuated the cortical infarct area following MCAO-induced ischemic damage in rats [12]                                                                                                                      |
|                       | L-165041      | Reduced OGD-induced MMP-9 enzymatic activity in mice [13]                                                                                                                                                                  |
|                       |               | Protected against vascular endothelial cell death by inhibiting expression of miR-15a, which increased Bcl-2 expression, reduced golgi fragmentation, and decreased caspase-3 activity [43] |
| Multiple sclerosis    | GW0742        | Reduced emergence of new cortical lesions, increased PLP mRNA, and reduced IL-1β expression in mice immunized with MOG [14]                                                                                                 |
|                       |               | Reduced IL-1, IL-23, IFNγ, and IL-17 and increased IL-4 and IL-10 in mice immunized with MOG [50]                                                                                                                                 |
|                       |               | Reduced LPS-induced TNF-α and iNOS mRNA in aggregating brain cells [54]                                                                                                                                                   |
|                       | L-165041      | Reduced IL-1, IL-23, IFNγ, and IL-17 and increased IL-4 and IL-10 in mice immunized with MOG [50]                                                                                                                                                   |
| Alzheimer’s disease   | GW0742        | Blocked Aβ peptide-induced cell death, as measured by LDH release and Fluorojade B staining, in primary cultures of rat cortical neurons [21]                                                                                  |
|                       |               | Decreased amyloid burden, increased neprilysin expression, and decreased GFAP expression in 5xFAD mice [22]                                                                                                                                 |
|                       | L-160,043     | Prevented STZ-induced neurodegeneration and cognitive impairment in rats. This was associated with reduced tau phosphorylation, increased choline acetyltransferase, attenuated 8-OHdG and HNE, and reduced GFAP expression [15] |
| Parkinson’s disease   | GW501516      | Ameliorated MPTP-induced depletion of striatal dopamine and its metabolites in mice [12]                                                                                                                                   |
|                       | L-165041      | Reduced Caspase-3 and protected SH-SY5Y cells from MPP+-induced cell death [12]                                                                                                                                           |
| Radiation-induced brain injury | GW0742 | Prevented microglial activation (CD68+ cells) in mice irradiated with a single dose of 10 Gy (unpublished)                                                                                                                                 |
|                       | L-165041      | Prevented intracellular ROS generation, Cox-2, iNOS, and MCP-1 expression, IL-1β and TNF-α mRNA, and NF-κB, and AP-1 activation in BV-2 cells irradiated with 10 Gy (unpublished)                                               |
| Spinal cord injury    | GW0742        | Improved motor function of mice and reduced TNF-α, IL-1β, and iNOS expression, NF-κB activation, neutrophil infiltration, nitrotyrosine and lipid peroxidation, FasL expression, and TUNEL staining [23]                              |
|                       |               | Reduced Cox-2, p-p38 MAPK, and p-c-jun expression, and NF-κB activation in murine spinal cord slices [88]                                                                                                                                 |

9. Spinal Cord Injury

Spinal cord injury (SCI) is associated with altered conduction of axons and motor dysfunction due to oligodendrocyte and neuronal cell death [85]. SCI is accompanied by inflammation and edema, which results in infiltration of inflammatory cells, release of proinflammatory factors, vascular permeability, and ultimately necrosis [86, 87]. Data suggest that PPARδ can modulate these responses. Administration of GW0742 to mice after SCI significantly improved their motor function. The PPARδ antagonist, GSK0660, blocked the effect of GW0742 on motor function suggesting that the protective effects of the agonists are dependent on activation of the PPARδ receptor. The effects of GW0742 were associated with reduced oxidative stress and proinflammatory responses in the spinal cord. This included a reduction in (i) TNF-α, IL-1β, and iNOS expression, (ii) NF-κB activation, (iii) neutrophil infiltration, (iv) nitrotyrosine and lipid peroxidation, (v) FasL expression, and (vi) TUNEL staining [23]. In accord with these findings, data demonstrate that GW0742 administered 1 hour prior to SCI reduced cell death and inflammation in cultured murine
spinal cord slices. The reduction in inflammation included decreased (i) Cox-2 expression and (ii) p38 MAPK, c-Jun N-terminal kinase, and NF-κB activation [88].

It has also been proposed that PPARδ attenuates SCI by promoting oligodendrocyte precursor cell (OPC) proliferation and differentiation following injury. Studies have shown that OPCs accumulate at SCI sites, likely as an attempt to regenerate the damaged axons [89]. Following SCI in rats, PPARδ positive cells increased in the white matter along the lesion border for up to two weeks. Double-labeling experiments indicated there was an increase in PPARδ in NG2 positive cells, potential OPCs, and PPARδ positive CC1 cells, oligodendrocytes [90]. Given the temporal and spatial expression of PPARδ after SCI, it is possible that it can regulate oligodendrogenesis after injury.

10. Summary

Taken together, the findings described above indicate that PPARδ agonists show promise as potential therapeutic agents for a variety of CNS pathologies, including stroke, MS, AD, PD, radiation-induced brain injury, and SCI. The neuroprotective efficacy of PPARδ agonists are, in large part, mediated by modulating oxidative stress and inflammatory processes; the neuroprotective benefits of PPARδ agonists are summarized in Table 1. Future studies using in vitro and in vivo approaches should further address the mechanisms by which PPARδ exerts its antioxidant and anti-inflammatory effects and help establish the foundations for future clinical applications of PPARδ agonists.

Acknowledgments

This work was supported by NIH Grant CA112593 (MER). The authors thank Dr. Linda van Eldik, Northwestern University, USA, for generously providing the BV-2 cells, originally developed by Dr. V. Bocchini, University of Perugia, Italy.

References

[1] Nuclear Receptors Nomenclature Committee, “A unified nomenclature system for the nuclear receptor superfamilies,” Cell, vol. 97, no. 2, pp. 161–163, 1999.
[2] T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Review of Cell and Developmental Biology, vol. 12, pp. 335–363, 1996.
[3] C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur, “Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 267–273, 2003.
[4] T. Osumi, J. K. Wen, and T. Hashimoto, “Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene,” Biochemical and Biophysical Research Communications, vol. 175, no. 3, pp. 866–871, 1991.
[5] A. Bugge and S. Mandrup, “Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactiva-

votion,” PPAR Research, vol. 2010, Article ID 169506, 12 pages, 2010.
[6] L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology and Therapeutics, vol. 110, no. 3, pp. 371–385, 2006.
[7] C. K. Glass, K. Sajo, B. Winner, M. C. Marchetto, and E. H. Gage, “Mechanisms underlying inflammation in neurodegeneration,” Cell, vol. 140, no. 6, pp. 918–934, 2010.
[8] R. Kapadia, J. H. Yi, and R. Vemuganti, “Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists,” Frontiers in Bioscience, vol. 13, no. 5, pp. 1813–1826, 2008.
[9] M. T. Heneka, G. E. Landreth, and M. Hüll, “Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders,” Nature Clinical Practice Neurology, vol. 3, no. 9, pp. 496–504, 2007.
[10] R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, part 6, pp. 1341–1346, 2006.
[11] S. Moreno, S. Farioli-vecchioli, and M. P. Cerù, “Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS,” Neuroscience, vol. 123, no. 1, pp. 131–145, 2004.
[12] A. Iwashita, Y. Muramatsu, T. Yamazaki et al., “Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1087–1096, 2007.
[13] K. J. Yin, Z. Deng, M. Hamblin, J. Zhang, and Y. E. Chen, “Vascular PPARδ protects against stroke-induced brain injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 574–581, 2011.
[14] P. E. Polak, S. Kalinin, C. Dello Russo et al., “Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 168, no. 1–2, pp. 65–73, 2005.
[15] S. M. de la Monte, M. Tong, N. Lester-Coll, M. Plater Jr., and J. R. Wands, “Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 10, no. 1, pp. 89–109, 2006.
[16] R. K. Chaturvedi, N. Y. Calingasan, L. Yang, T. Hennessey, A. Johri, and M. F. Beal, “Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington’s disease following chronic energy deprivation,” Human Molecular Genetics, vol. 19, no. 16, pp. 3190–3205, 2010.
[17] J. B. Pialat, T. H. Cho, O. Beuf et al., “MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice,” NMR in Biomedicine, vol. 20, no. 3, pp. 335–342, 2007.
[18] D. Arsenijevic, F. de Bilbao, J. Plamondon et al., “Increased infarct size and lack of hyperphagic response after focal cerebr- al ischemia in peroxisome proliferator-activated receptor β-deficient mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 3, pp. 433–445, 2006.
[19] S. Kanakasabai, C. C. Walline, S. Chakraborty, and J. J. Bright, “PPARδ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis,” Brain Research, vol. 1376, pp. 101–112, 2011.
[20] S. E. Dunn, R. Bhat, D. S. Straus et al., “Peroxisome proliferator-activated receptor δ limits the expansion of
pathogenic Th cells during central nervous system autoimmunity,” Journal of Experimental Medicine, vol. 207, no. 8, pp. 1599–1608, 2010.

[21] J. L. M. Madrigal, S. Kalinin, J. C. Richardson, and D. L. Feinstein, “Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator-activated receptor delta,” Journal of Neurochemistry, vol. 103, no. 5, pp. 2092–2101, 2007.

[22] S. Kalinin, J. C. Richardson, and D. L. Feinstein, “A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease,” Current Alzheimer Research, vol. 6, no. 5, pp. 431–437, 2009.

[23] I. Paterniti, E. Esposito, E. Mazzon et al., “Evidence for the role of peroxisome proliferator-activated receptor-β/δ in the development of spinal cord injury,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 2, pp. 465–477, 2010.

[24] F. Gofflot, N. Chartoire, L. Vasseur et al., “Systematic gene expression mapping clusters nuclear receptors according to their function in the brain,” Cell, vol. 131, no. 2, pp. 405–418, 2007.

[25] G. Xing, L. Zhang, L. Zhang et al., “Rat PPARβ contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei,” Biochemical and Biophysical Research Communications, vol. 217, no. 3, pp. 1015–1025, 1995.

[26] J. W. Woods, M. Tänen, D. J. Figueroa et al., “Localization of PPARγ in murine central nervous system: expression in oligodendrocytes and neurons,” Brain Research, vol. 975, no. 1–2, pp. 10–21, 2003.

[27] O. Braissant and W. Wahli, “Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development,” Endocrinology, vol. 139, no. 6, pp. 2748–2754, 1998.

[28] P. Krmárik-Bouillaud, H. Schohn, and M. Daucş, “Regional distribution of PPARα in the cerebellum of the rat,” Journal of Chemical Neuroanatomy, vol. 19, no. 4, pp. 225–232, 2000.

[29] S. I. Akanuma, S. Hori, S. Ohutsuki, M. Fujiyoshi, and T. Terasaki, “Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood-brain barrier,” Neurochemistry International, vol. 52, no. 4–5, pp. 669–674, 2008.

[30] L. Cristiano, A. Gimmie, S. Moreno, A. M. Ragnelli, and M. Paola Cerù, “ Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures,” Neuroscience, vol. 131, no. 3, pp. 577–587, 2005.

[31] L. Cristiano, A. Bernardo, and M. P. Cerù, “Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes,” Journal of Neurocytology, vol. 30, no. 8, pp. 671–683, 2001.

[32] L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology and Therapeutics, vol. 110, no. 3, pp. 371–385, 2006.

[33] R. Kostadinova, W. Wahli, and L. Michalik, “PPARs in diseases: control mechanisms of inflammation,” Current Medicinal Chemistry, vol. 12, no. 25, pp. 2995–3009, 2005.

[34] D. Bishop-Bailey and J. Bystrom, “Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation,” Pharmacology and Therapeutics, vol. 124, no. 2, pp. 141–150, 2009.

[35] M. G. Sergeeva, S. E. Aleshin, S. Grabeklis, and G. Reiser, “PPAR activation has dichotomous control on the expression levels of cytosolic and secretory phospholipase A2 in astrocytes; inhibition in naïve, untreated cells and enhancement in LPS-stimulated cells,” Journal of Neurochemistry, vol. 115, no. 2, pp. 399–410, 2010.

[36] M. Pesant, S. Sueur, P. Dutartre et al., “Peroxisome proliferator-activated receptor δ (PPARδ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis,” Cardiovascular Research, vol. 69, no. 2, pp. 440–449, 2006.

[37] G. D. Gurnun, F. E. Domann, S. A. Moore, and M. E. C. Robbins, “Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter,” Molecular Endocrinology, vol. 16, no. 12, pp. 2793–2801, 2002.

[38] A. Planavila, R. Rodriguez-Calvo, M. Jové et al., “Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 832–841, 2005.

[39] Y. Fan, Y. Wang, Z. Tang et al., “Suppression of pro-inflammatory adhesion molecules by PPAR-δ in human vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 2, pp. 315–321, 2008.

[40] C. H. Lee, A. Chawla, N. Urbiztondo et al., “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003.

[41] Y. Takeda, J. Liu, F. Yin et al., “PPARδ-mediated antiinflammatory mechanisms inhibit angiotesin II-accelerated atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4277–4282, 2008.

[42] T. Glatz, I. Stock, M. Nguyen-Ngoc et al., “Peroxisome proliferator-activated receptors γ and peroxisome proliferator-activated receptors β/δ and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain,” Journal of Hypertension, vol. 28, no. 7, pp. 1488–1497, 2010.

[43] K. J. Yin, Z. Deng, M. Hamblin et al., “Peroxisome proliferator-activated receptor δ regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury,” Journal of Neuroscience, vol. 30, no. 18, pp. 6398–6408, 2010.

[44] S. Basu-Madok, O. Braissant, P. Escher et al., “Effect of the peroxisome proliferator-activated receptor β activator GW0742 in rat cultured cerebellar granule neurons,” Journal of Neuroscience Research, vol. 77, no. 2, pp. 240–249, 2004.

[45] P. Stinissen, J. Raus, and J. Zhang, “Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies,” Critical Reviews in Immunology, vol. 17, no. 1, pp. 33–75, 1997.

[46] E. N. Benveniste, “Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis,” Journal of Molecular Medicine, vol. 75, no. 3, pp. 165–173, 1997.

[47] T. G. Johns, N. Kerlero de Rosbo, K. K. Menon, S. Abo, M. F. Gonzales, and C. C. A. Bernardi, “Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis,” Journal of Immunology, vol. 154, no. 10, pp. 5536–5541, 1995.

[48] M. K. Storch, A. Stefferl, U. Brehm et al., “Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology,” Brain Pathology, vol. 8, no. 4, pp. 681–694, 1998.

[49] A. Cimini, A. Bernardo, M. G. Cifone, L. Di Muzio, and S. Di Loreto, “TNFα downregulates PPARδ expression in oligodendrocyte progenitor cells: implications for demyelinating diseases,” GLIA, vol. 41, no. 1, pp. 3–14, 2003.

[50] S. Kanakasabai, W. Chearwae, C. C. Walline, W. Iams, S. M. Adams, and J. J. Bright, “Peroxisome proliferator-activated receptor δ agonists inhibit T helper type 1 (Th1) and...
Y. Xiao, J. Xu, S. Wang et al., “Genetic ablation of steroid receptor coactivator-3 promotes PPAR-β-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis,” *GLIA*, vol. 58, no. 8, pp. 932–942, 2010.

K. Kang, S. M. Reilly, V. Karabacak et al., “Adipocyte-derived Th2 cytokines and myeloid PPARδ regulate macrophage polarization and insulin sensitivity,” *Cell Metabolism*, vol. 7, no. 6, pp. 485–495, 2008.

J. I. Odegaard, R. R. Ricardo-Gonzalez, A. Red Eagle et al., “Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance,” *Cell Metabolism*, vol. 7, no. 6, pp. 496–507, 2008.

A. Defaux, M. G. Zurich, O. Braissant, P. Honegger, and F. Monnet-Tschudi, “Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination,” *Journal of Neuroinflammation*, vol. 6, article 15, 2009.

W. Bondareff, C. Q. Mountjoy, and M. Roth, “Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia,” *The Lancet*, vol. 1, no. 8223, pp. 783–784, 1981.

B. A. Yankner, “New clues to Alzheimer’s disease: unraveling the roles of amyloid and tau,” *Nature Medicine*, vol. 2, no. 8, pp. 850–852, 1996.

L. Frölich, D. Blum-Degen, H. G. Bernstein et al., “Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease,” *Journal of Neural Transmission*, vol. 105, no. 4-5, pp. 423–438, 1998.

H. G. Bernstein, S. Ansorge, P. Riederer, M. Reiser, L. Frölich, and B. Bogerts, “Insulin-degrading enzyme in the Alzheimer’s disease brain: prominent localization in neurons and senile plaques,” *Neuroscience Letters*, vol. 263, no. 2-3, pp. 161–164, 1999.

W. R. Markesbery and J. M. Carney, “Oxidative alterations in Alzheimer’s disease,” *Brain Pathology*, vol. 9, no. 1, pp. 133–146, 1999.

L. M. Sayre, D. A. Zelasko, P. G. Perry, R. G. Salomon, and M. A. Smith, “4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease,” *Journal of Neurochemistry*, vol. 68, no. 5, pp. 2092–2097, 1999.

A. Hald and J. Lotharius, “Oxidative stress and inflammation in Parkinson’s disease: is there a causal link?” *Experimental Neurology*, vol. 193, no. 2, pp. 279–290, 2005.

T. Dehmer, M. T. Heneka, M. Sastre, J. Dichgans, and J. B. Schulz, “Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with KA alpha induction and block of NF kappa B and iNOS activation,” *Journal of Neurochemistry*, vol. 86, no. 2, pp. 494–501, 2004.

C. Consilvio, A. M. Vincent, and E. L. Feldman, “Neuroinflammation, COX-2, and ALS - A dual role?” *Experimental Neurology*, vol. 187, no. 1, pp. 1–10, 2004.

M. Strokin, M. Sergeeva, and G. Reiser, “Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2,” *Journal of Neurochemistry*, vol. 102, no. 6, pp. 1771–1782, 2007.

O. V. Forlenza, E. L. Schaeffer, and W. F. Gattaz, “Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases,” *Journal of Neural Transmission*, vol. 114, no. 2, pp. 231–238, 2007.
in CNS radiation injury,” *Journal of Neuroimmunology*, vol. 95, no. 1-2, pp. 95–106, 1999.

[83] W. Zhao, V. Payne, E. Tommasi, D. I. Diz, F. C. Hsu, and M. E. Robbins, “Administration of the peroxisomal proliferator-activated receptor γ agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment,” *International Journal of Radiation Oncology Biology Physics*, vol. 67, no. 1, pp. 6–9, 2007.

[84] M. Lindberg and A. Astrup, “The role of glitazones in management of type 2 diabetes. A dream or a nightmare?” *Obesity Reviews*, vol. 8, no. 5, pp. 381–384, 2007.

[85] M. J. Crowe, J. C. Bresnahan, S. L. Shuman, J. N. Masters, and M. S. Beattie, “Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys,” *Nature Medicine*, vol. 3, no. 1, pp. 73–76, 1997.

[86] T. B. Jones, E. E. McDaniel, and P. G. Popovich, “Inflammatory-mediated injury and repair in the traumatically injured spinal cord,” *Current Pharmaceutical Design*, vol. 11, no. 10, pp. 1223–1236, 2005.

[87] C. Profyris, S. S. Cheema, D. Zang, M. F. Azari, K. Boyle, and S. Petratos, “Degenerative and regenerative mechanisms governing spinal cord injury,” *Neurobiology of Disease*, vol. 15, no. 3, pp. 415–436, 2004.

[88] E. Esposito, I. Paterniti, R. Meli, P. Bramanti, and S. Cuzzocrea, “GW0742, A High Affinity Ppar-δ Gonist, Mediates Protection in an Organotypic Model of Spinal Cord Damage,” *Spine*. In press.

[89] D. M. McTigue, P. Wei, and B. T. Stokes, “Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord,” *Journal of Neuroscience*, vol. 21, no. 10, pp. 3392–3400, 2001.

[90] A. Almad and D. M. McTigue, “Chronic expression of PPAR-δ by oligodendrocyte lineage cells in the injured rat spinal cord,” *Journal of Comparative Neurology*, vol. 518, no. 6, pp. 785–799, 2010.